Mesoblast Limited (MESO)

Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product

Mesoblast (NASDAQ:MESO) and Biogen (NASDAQ:BIIB) Head-To-Head Contrast

Mesoblast (NASDAQ:MESO) Share Price Passes Above 50 Day Moving Average – Time to Sell?

Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript

Mesoblast Reports Substantial Revenue Growth to US$120M

Mesoblast H2 Earnings Call Highlights

MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up

Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis